MRG001

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameMRG001
Drug Alias NameMRG-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoproliferative DisordersLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Miracogen Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Friendship Hospital Co LtdLepu Biopharma Co LtdShanghai Miracogen Inc
Inactive CompaniesN/A
Active IndicationsLymphoproliferative DisordersLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4] 
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A